Divalproex Sodium
Product Images NDC 64725-0595

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 64725-0595). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (64725 0595)

Label for Divalproex sodium extended-release 500 mg tablets, repackaged by TYA Pharmaceuticals. The original manufacturer is Aurobindo Pharma. The label includes prescription-only status and contact information for TYA Pharmaceuticals in Tallahassee, Florida. It also contains a barcode and a note advising to see the package insert for dosing information.*

FDA Label Image

Figure 1 (Divalproex Fig1)

A line graph showing the percent reduction in CPS rate versus percent of patients comparing Divalproex Sodium Delayed-Release Tablets and placebo. The graph illustrates patient improvement or worsening with Divalproex Sodium showing a greater trend toward improvement compared to placebo.*

FDA Label Image

Figure 2 (Divalproex Fig2)

A cumulative percent reduction graph showing the percent reduction in CPS Rate on the vertical axis against the percent of patients on the horizontal axis, comparing high dose and low dose Divalproex Sodium delayed-release tablets. The graph depicts improvement and worsening trends in CPS Rate for patients on these doses.*

FDA Label Image

Figure 3. Mean Reduction In 4-week Migraine Headache Rates (Divalproex Fig3)

A bar chart titled 'Mean Reduction in 4-Week Migraine Headache Rates' comparing placebo and Divalproex Sodium Extended-Release Tablets. The chart shows a higher mean reduction for Divalproex Sodium compared to placebo, with values approximately 1.2 and 0.6 respectively. A note indicates statistical significance with p=0.006.*

FDA Label Image

Chemical Structure (Divalproex Str)

Chemical structure of divalproex sodium showing the repeating unit of the molecule including the sodium salt and carboxylate functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.